Serabi Gold plc
TSX:SBI.TOGold
-$0.02 today
- Market cap
- $225.11M
- Beta
- 0.84
- P/E (TTM)
- 4.9
- EPS (TTM)
- $0.88
Volume 0.10M
Average 0.04M
SBI.TO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Serabi Gold plcTSX: SBI.TO
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q1 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How SBI.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Research & development amounts to 0.0% of revenue for SBI.TO, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | CA$0 CAD | — | — | 0.0% | |
| LTM Feb 2026 | CA$0 CAD | — | — | — | |
| Peer median (excluding SBI.TO) | — | — | — | 0.0% | |
Competitors are the stored peer set for SBI.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 63.14M | 58.71M | 63.71M | 94.54M | 159.32M |
| Cost of Revenue | 43.81M | 50.84M | 49.65M | 54.98M | 78.31M |
| Gross Profit | 19.33M | 7.87M | 14.05M | 39.55M | 81M |
| Gross Margin | 30.6% | 13.4% | 22.1% | 41.8% | 50.8% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 5.83M | 5.45M | 6.49M | 7.44M | 11.03M |
| Operating Expenses | 6.1M | 5.7M | 6.51M | 7.97M | 11.67M |
| Depreciation & Amortization | 6.05M | 6.57M | 6.24M | 4.27M | 9.97M |
| EBITDA | 19.48M | 9.21M | 15.15M | 37.22M | 79.3M |
| EBITDA Margin | 30.9% | 15.7% | 23.8% | 39.4% | 49.8% |
| Operating Income | 13.08M | 2.21M | 7.54M | 31.59M | 69.33M |
| Operating Margin | 20.7% | 3.8% | 11.8% | 33.4% | 43.5% |
| Interest Income | 417.4K | 126.39K | 313.11K | 499.14K | 995.66K |
| Interest Expense | 71.36K | 3.41M | 739.25K | 674.4K | 485.56K |
| Other Income / Expenses | 282.56K | (2.99M) | 623.24K | 690.12K | 860.73K |
| Income Before Tax | 13.36M | (776.3K) | 8.17M | 32.28M | 70.19M |
| Pre-Tax Margin | 21.2% | -1.3% | 12.8% | 34.1% | 44.1% |
| Income Tax Expense | 3.41M | 206.74K | 1.59M | 4.46M | 15.09M |
| Net Income | 9.95M | (983.05K) | 6.58M | 27.82M | 55.11M |
| Net Margin | 15.8% | -1.7% | 10.3% | 29.4% | 34.6% |
| EPS (Basic) | 0.14 | (0.01) | 0.09 | 0.37 | 0.73 |
| EPS (Diluted) | 0.13 | (0.01) | 0.09 | 0.37 | 0.73 |
| Weighted Avg Shares | 77M | 81.49M | 75.76M | 75.73M | 75.74M |
| Weighted Avg Shares (Diluted) | 77M | 81.49M | 75.73M | 75.73M | 75.74M |
Serabi Gold plc
TSX:SBI.TO
Intrinsic Alpha fair value
Locked
Current Price
$2.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.